Login to Your Account

Solid interim data drive Receptos MS drug into Phase III

By Marie Powers
Staff Writer

Friday, December 6, 2013
Receptos Inc. moved one step closer to its goal of setting a safer standard in oral therapy for multiple sclerosis (MS), reporting positive data from a planned interim analysis of the Phase II portion of RADIANCE, the company’s Phase II/III trial of RPC1063 in relapsing MS. (See BioWorld Insight, Nov. 4, 2013.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription